Sign inJoin waitlistJoin the waitlist

Toni Pacioles

Associate Professor, Section Chief · Marshall University School of Medicine

Credentials: · · · · ·

History

Section Chief · Marshall University School of Medicine
Present
Marshall University School of Medicine
Present

Geriatric Medicine
2010–2011
Hematology and Medical Oncology
SUNY Upstate Medical University
2007–2010
Internal Medicine
Marshall University School of Medicine
2004–2007
UNIV OF THE PHILIPPINES, MANILA
2000–2004

Research

Atypical Takotsubo Cardiomyopathy Secondary to Combination of Chemo-Immunotherapy in a Patient With Non-Small Cell Lung Cancer
Case report · Cureus · 2020 · 13 citations
A Rare Case of Ovarian Double-Hit/Diffuse Large B-Cell Lymphoma: A Case Report and Review of Literature
Case report · Journal of Investigative Medicine High Impact Case Reports · 2023 · Last of 4 authors · 11 citations
Gemcitabine-induced skin necrosis
Case report · SAGE Open Medical Case Reports · 2018 · Last of 3 authors · 9 citations

MA
Mahmoud Abdallah
8 papers · 8 as a fellow
KN
Kemnasom Nwanwene
7 papers · 7 as a fellow
Jowan Al-Nusair
4 papers · 4 as a resident
Muhammad Jamil
4 papers
AS
Adarsh Sidda
3 papers
Ahmed Elsayed
3 papers
DG
Doreen Griswold
3 papers
John Flickinger
3 papers · 1 as a fellow
JV
John Varlotto
3 papers
Malcolm DeCamp
3 papers
MS
Mina Shenouda
3 papers
Mohamed Alsharedi
3 papers · 1 as a fellow

Clinical trials

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2037
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Site PI · Recruiting · Phase 3
NRG Oncology
2025–2030
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Site PI · Recruiting · Phase 2, Phase 3
SWOG Cancer Research Network
2025–2028
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2039